Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9392MR)

This product GTTS-WQ9392MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9392MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5818MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ9668MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ2676MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ10741MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ3374MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ8260MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ2263MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ9908MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KB-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW